The effect of Percutaneous embolization in patients with symptomatic liver hemangiomas

Study of the effect of Percutaneous embolization with bleomycin sclerosing in patients with symptomatic liver hemangiomas

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130812014333N154

Enrollment

Registered

2020-11-06

Start date

2020-11-10

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver symptomatic hemangioma. Haemangioma, any site

Interventions

Intervention 1: In the intervention group, sclerotherapy (with 18 or 20 gage needles) will be performed with a mixture of 20 cc of IU 45 Bleomycin in 10 cc of distilled water and 10 cc of lipividol. I

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A giant hepatic hemangioma with clear margins The number of platelets is more than 100,000 International Ratio Normalized less than 1/5

Exclusion criteria

Exclusion criteria: Patients with severe ascites Improper position of the hemangioma Patients with hepatic or renal impairment

Design outcomes

Primary

Measure	Time frame
Ultrasound volume. Timepoint: At the beginning of the study and 6 months after the end of the study. Method of measurement: Using the GE-Logic S6 ultrasound device.;Largest diameter of ultrasond. Timepoint: At the beginning of the study and 6 months after the end of the study. Method of measurement: Using the GE-Logic S6 ultrasound device.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Loura Khanian

Kermanshah University of Medical Sciences

Loura.Khanian@yahoo.com+98 83 3427 6306

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026